Traxcess 7 Mini XSoft Guidewire
FDA 510(k)Class II (US FDA 510(k))
Identifiers
- 510(k) Number
- K163154 FDA 510(k)
- FDA Product Code
- MOF FDA 510(k)
Classification
- Device Class
- Class II FDA 510(k)
- Legislation / Framework
- 21 CFR Part 870.1330 FDA 510(k)
- Regulation Number
- 870.1330 FDA 510(k)
- Advisory Committee
- Cardiovascular FDA 510(k)
- FDA Decision
- SESE Substantially Equivalent FDA 510(k)
The Traxcess 7 Mini XSoft Guidewire is a low-profile, highly trackable guidewire with a distinct 0.007" to 0.014" tapered design, used to navigate microcatheters to hard-to-reach, distal vessels with precision. It is indicated for general intravascular use, including the neuro and peripheral vasculature, and can be steered to facilitate the selective placement of diagnostic or therapeutic catheters.
This device is not indicated for use in coronary arteries. It is supplied as a single-use device and requires appropriate storage conditions. The Traxcess 7 Mini XSoft Guidewire has received FDA 510(k) clearance with the product code MOF and is classified as a Class II device.
This description and any FAQs above were generated automatically from registry data and have not been verified by the manufacturer or by deviCERTS. Always check the official registry entry and the manufacturer's instructions for use before relying on them. Sources consulted: PDF Traxcess 7 MINI - assets.ctfassets.net, Traxcess™ Mini | Terumo Neuro - MicroVention, Traxcess 7 Mini XSoft Guidewire (K163154) — FDA 510(k) | Innolitics, Traxcess 7 Mini XSoft Guidewire (K163154) — FDA 510(k) | Innolitics
Authorization Coverage (1 country)
Regulatory Authorizations
FDA_510K
| Source | Region | Type | Cert / Approval No. | Class | Status |
|---|---|---|---|---|---|
| FDA 510(k) | United States | FDA_510K | K163154 | Class II | Active |
Is this your device? Claim it to add documentation and request validation.
Manufacturer
- Manufacturer
- Microvention Inc.
- FDA Applicant
- MicroVention, Inc.
Sources (1)
- FDA 510(k) K163154 24 fields · synced Sep 27, 2026